« Back to Facilities Management News Home
Allendale, NJ -- Lonza’s Hygiene & Preservation business is excited to announce its Lonzagard® R-82 family of disinfectants is now EPA approved to combat Carbapenem-Resistant Enterobacteriaceae (CREs).
Untreatable and hard-to-treat infections from CRE bacteria are on the rise among patients in medical facilities. CRE have become resistant to all or nearly all the antibiotics we have today. Almost half of hospital patients who get bloodstream infections from CRE bacteria die from the infection. Each year in the United States, at least 2 million people become infected with bacteria that are resistant to antibiotics and at least 23,000 people die as a direct result of these infections, according to the U.S. Centers for Disease Control and Prevention.
The Lonzagard® R-82 family includes economical concentrates and convenient, ready-to-use disinfectants that are ideal for all types of healthcare facilities. “Lonza aims to provide solutions that disinfect hard surfaces to kill CRE throughout healthcare facilities. Our highly effective disinfectants are a vital tool to kill disease-causing bacteria and viruses on hard surfaces that if left untreated can lead to the spread of hospital-acquired infections.” said Craig Carter, N.A. Marketing Manager for Lonza’s Hygiene business, which is a part of the company’s Consumer Care organization.
Lonza provides these and other technologies through partners who service the healthcare industry. Contact Lonza or your cleaning chemicals supplier today and ask about products powered by Lonzagard® technology.
About Lonza’s Hygiene & Preservation Business
A key part of Lonza’s Consumer Care organization, the Hygiene & Preservation business offers the broadest portfolio of registered actives, preservatives and formulations for use in disinfectants, sanitizers, and institutional and household cleaning products. This wide range of solutions are used to disinfect and sanitize schools, food processing plants, restaurants, grocery stores, hospitals, homes and more. More information can be found at www.lonzabiocides.com.
About Lonza
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life.
Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and approximately 10,000 employees worldwide. The company generated sales of about CHF 3.6 billion in 2013 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients. Lonza’s stock is publicly traded on the Swiss and the Singapore stock exchanges. Further information can be found at www.lonza.com.
